Logo image of QLGN

QUALIGEN THERAPEUTICS INC (QLGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:QLGN - US74754R3012 - Common Stock

3.21 USD
+0.17 (+5.59%)
Last: 11/18/2025, 8:00:01 PM
3.2 USD
-0.01 (-0.31%)
After Hours: 11/18/2025, 8:00:01 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to QLGN. QLGN was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of QLGN have multiple concerns. QLGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

QLGN had negative earnings in the past year.
QLGN had a negative operating cash flow in the past year.
QLGN had negative earnings in each of the past 5 years.
QLGN had a negative operating cash flow in each of the past 5 years.
QLGN Yearly Net Income VS EBIT VS OCF VS FCFQLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

QLGN's Return On Assets of -176.92% is on the low side compared to the rest of the industry. QLGN is outperformed by 88.60% of its industry peers.
Industry RankSector Rank
ROA -176.92%
ROE N/A
ROIC N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QLGN Yearly ROA, ROE, ROICQLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QLGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QLGN Yearly Profit, Operating, Gross MarginsQLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for QLGN has been increased compared to 1 year ago.
QLGN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for QLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QLGN Yearly Shares OutstandingQLGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
QLGN Yearly Total Debt VS Total AssetsQLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

QLGN has an Altman-Z score of -49.96. This is a bad value and indicates that QLGN is not financially healthy and even has some risk of bankruptcy.
QLGN has a worse Altman-Z score (-49.96) than 93.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -49.96
ROIC/WACCN/A
WACCN/A
QLGN Yearly LT Debt VS Equity VS FCFQLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

QLGN has a Current Ratio of 0.71. This is a bad value and indicates that QLGN is not financially healthy enough and could expect problems in meeting its short term obligations.
QLGN has a Current ratio of 0.71. This is amonst the worse of the industry: QLGN underperforms 90.28% of its industry peers.
A Quick Ratio of 0.71 indicates that QLGN may have some problems paying its short term obligations.
QLGN has a worse Quick ratio (0.71) than 90.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.71
QLGN Yearly Current Assets VS Current LiabilitesQLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.49% over the past year.
The Revenue for QLGN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)83.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, QLGN will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

QLGN Yearly Revenue VS EstimatesQLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 1M 2M 3M 4M 5M
QLGN Yearly EPS VS EstimatesQLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 -50K -100K -150K -200K -250K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

QLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QLGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QLGN Price Earnings VS Forward Price EarningsQLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QLGN Per share dataQLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

QLGN's earnings are expected to grow with 31.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QLGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUALIGEN THERAPEUTICS INC

NASDAQ:QLGN (11/18/2025, 8:00:01 PM)

After market: 3.2 -0.01 (-0.31%)

3.21

+0.17 (+5.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change166.89%
Ins OwnersN/A
Ins Owner Change0%
Market Cap6.52M
Revenue(TTM)N/A
Net Income(TTM)-7.01M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.6
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0
BVpS-0.81
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -176.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-278.66%
ROA(5y)-298%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.71
Altman-Z -49.96
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.33%
EPS Next Y62.96%
EPS Next 2Y31.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.93%
OCF growth 3YN/A
OCF growth 5YN/A

QUALIGEN THERAPEUTICS INC / QLGN FAQ

Can you provide the ChartMill fundamental rating for QUALIGEN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to QLGN.


What is the valuation status of QUALIGEN THERAPEUTICS INC (QLGN) stock?

ChartMill assigns a valuation rating of 1 / 10 to QUALIGEN THERAPEUTICS INC (QLGN). This can be considered as Overvalued.


Can you provide the profitability details for QUALIGEN THERAPEUTICS INC?

QUALIGEN THERAPEUTICS INC (QLGN) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for QLGN stock?

The Earnings per Share (EPS) of QUALIGEN THERAPEUTICS INC (QLGN) is expected to grow by 62.96% in the next year.